APA (7th ed.) Citation

Scherman, E., Malak, S., Perot, C., Gorin, N. C., Rubio, M. T., & Isnard, F. (2012). Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype. Leukemia (08876924), 26(4), 822. https://doi.org/10.1038/leu.2011.284

Chicago Style (17th ed.) Citation

Scherman, E., S. Malak, C. Perot, N C. Gorin, M T. Rubio, and F. Isnard. "Interest of the Association Azacitidine-lenalidomide as Frontline Therapy in High-risk Myelodysplasia or Acute Myeloid Leukemia with Complex Karyotype." Leukemia (08876924) 26, no. 4 (2012): 822. https://doi.org/10.1038/leu.2011.284.

MLA (9th ed.) Citation

Scherman, E., et al. "Interest of the Association Azacitidine-lenalidomide as Frontline Therapy in High-risk Myelodysplasia or Acute Myeloid Leukemia with Complex Karyotype." Leukemia (08876924), vol. 26, no. 4, 2012, p. 822, https://doi.org/10.1038/leu.2011.284.